First Author, year, reference | Target group | Setting | Country | Infection | Model | Data | Indicator^ | Result* | Year of monetary value # | Euro in 2010 | Cost-effective? |
---|---|---|---|---|---|---|---|---|---|---|---|
Thomas, 1990 [58] | Pregnant women | Antenatal care | Australia | HBV | None | Actual screening | Cost per case detected | $354 (AU) | 1988 | € 379 | Yes |
Audet, 1991 [57] | Pregnant women | Antenatal care | Canada | HBV | None | Hypothetical cohort | Cost per case detected/infant carrier prevented | $1.693/$8.915 (CA) | 1988 | € 1.799-€9.475 | Yes, probably |
Tormans, 1993 [54] | Pregnant women | Antenatal care | Belgium | HBV | Markov | Hypothetical cohort | Cost per LY gained | BEF 583.581 | 1991 | € 22.095 | Yes |
Dwyer, 1996 [56] | Pregnant women | Antenatal care | UK | HBV | Markov | Hypothetical cohort | Cost per carrier prevented/LY gained | £2.437/£16.450 | Not mentioned (1996) | € 3.879 -€26.181 | Yes |
Jordan, 1997 [55] | Pregnant women | Antenatal care | Britain | HBV | Markov | Hypothetical cohort | Cost per LY gained | ₤1.300 | Not mentioned (1997) | € 2.032 | Yes |
Plunkett, 2005 [59] | Pregnant women | Antenatal care | USA | HCV | Markov | Hypothetical cohort | Cost per QALY | No screening dominant | 2003 | n.a. | No |
Eckman, 2011 [47] | General population (35 year old males) | Primary care | USA | HBV | Markov | Hypothetical cohort | Cost per QALY | $29.232 (US) | 2008 | € 23.966 | Yes |
Singer, 2001 [49] | General population | Not specified | USA | HCV | Markov | Hypothetical cohort | Cost per QALY | No screening dominant | 2001 | n.a. | No |
Nakamura, 2008 [50] | General population & risk groups | Not specified | Japan | HCV | Markov | Actual screening | Cost per LY gained | $848 - $4.825 (US) | 2007 | € 726-€4.130 | Yes |
Loubiere, 2003 [48] | General population, IDUs & other risk groups | Not specified | France | HCV | Markov | Hypothetical cohort | Cost per LY gained | $4.513 (US) (IDUs)/$5.821 (gen pop) | 1998 | € 4.856/€6.263 | Yes |
Coffin, 2012 [51] | General population (20–69 y.o. and 1945–1965) | Not specified | USA | HCV | Markov | Hypothetical cohort | Cost per QALY | $7.900-$5.400 (US) | 2010 | € 6.376-€4.358 | Yes |
McGarry, 2012 [52] | General population (born 1946–1970) | Not specified | USA | HCV | Markov | Hypothetical cohort | Cost per QALY | $37.720 (US) | 2010 | € 30.444 | Yes |
Rein, 2012 [53] | General population (born 1945–1965) | Not specified | USA | HCV | Markov | Hypothetical cohort | Cost per QALY | $15.700 (US) | 2009 | € 12.976 | Yes |
Ruggeri, 2011 [73] | High risk groups | Not specified | Italy | HBV | Markov | Hypothetical cohort | Cost per QALY | €18.255 (IT) | 2004 | € 52.885 | Yes |
Hutton, 2007 [67] | Migrants | Not specified | USA | HBV | Markov | Hypothetical cohort | Cost per QALY | $36.088 (US) | 2006 | € 31.692 | Yes |
Veldhuijzen, 2010 [68] | Migrants | Population based | Netherlands | HBV | Markov | Hypothetical cohort | Cost per QALY | €8.966 (Nl) | 2009 | € 8.694 | Yes |
Rein, 2011 [69] | Migrants | 5 settings compared | USA | HBV | None | Actual screening | Cost per case detected | $609-$4.657 (US) | 2008 | €499-€3.818 | Yes |
Wong, 2011 [70] | Migrants | Not specified | Canada | HBV | Markov | Hypothetical cohort | Cost per QALY | $69.209 (CA) | 2008 | €46.260 | Yes, moderately |
Leal, 1999 [60] | IDUs | Drug services | UK | HCV | Markov | Hypothetical cohort | Cost per QALY | £9.300 | 1997 | € 14.540 | Yes |
Castelnuovo, 2006 [61] | IDUs | Various | UK | HCV | Markov | Hypothetical cohort | Cost per QALY | £15.493-£20.083 | 2004 | € 22.172-€28.741 | Yes |
Thompson Coon, 2006 [62] | IDUs | Primary care | UK | HCV | Markov | Hypothetical cohort | Cost per QALY | £16.493 | 2002/2003 | € 24.245 | Yes |
Kerr, 2009 [43] | IDUs & MSM | STD clinic | Scotland | HCV | None | Actual screening | Cost per case detected | £ 170 (IDU)/£15.000 (MSM) | Not mentioned (2009) | € 215-€18.975 | Yes (IDU), No (MSM) |
Josset, 2004 [63] | IDUs & other risk groups | Primary care | France | HCV | None | Actual screening | Cost per case detected | not reported | Not mentioned | n.a. | Not stated |
Stein, 2004 [44] | IDUs & other risk groups | STD clinic/drug services | UK | HCV | Markov | Hypothetical cohort | Cost per QALY | ₤28.120 (IDUs)/₤84.570 (GUM) | 2001 | € 41.874-€125.933 | Yes (IDUs)/No (GUM) |
Honeycutt, 2007 [64] | IDUs & other risk groups | STD clinic | USA | HCV | None | Hypothetical cohort | Cost per case detected | $54 (US) | 2006 | € 47 | Yes |
Tramarin, 2008 [65] | IDUs & other risk groups | Not specified | Italy | HCV | Markov | Hypothetical cohort | Cost per QALY | -€3.132 (IT) | 2007 | -€ 3.328 | Yes |
Helsper, 2012 [66] | IDUs & other risk groups incl migrants | Primary care/drug services | Netherlands | HCV | Markov | Actual screening | Cost per QALY | €7.321 (NL) | 2007 | € 7.327 | Yes |
Sutton, 2006 [71] | Prisoners | Prison | UK | HCV | Markov | Hypothetical cohort | Cost per case detected | £2,102 - £3,107 | 2004 | € 3.008-€4.446 | Yes |
Sutton, 2008 [72] | Prisoners | Prison | UK | HCV | Markov | Hypothetical cohort | Cost per QALY | £54.852 | 2004 | € 78.498 | No |